SCANCELL HOLDINGS PLC — AGM Information 2016

Oct 18, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8832M

Scancell Holdings Plc

18 October 2016

18th October 2016

Scancell Holdings Plc

("Scancell" or the "Company")

Results of AGM

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.

For Further Information:

Scancell Holdings Plc

Dr John Chiplin, Executive Chairman Dr Richard Goodfellow, CEO	Scancell Holdings Plc	+1 858 900 2646 +44 (0) 20 3727 1000
Freddy Crossley (Corporate Finance) Tom Salvesen (Corporate Broking)	Panmure Gordon & Co	+44 (0) 20 7886 2500 +44 (0) 20 7886 2500
Mo Noonan/Simon Conway	FTI Consulting	+44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell's ImmunoBody® treatments target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGDMMMGVRGGVZM

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'FLixXiw6EhYyGPyoP8OAFkUA97XkUongkmdX1Vbbc_yiXN_fx3xoP15SFCTQ4ZSqzitaJswtjbVsMOC_0LAPHcIPde7sC-_As2kgzXoW8441:rB-c0Xov5CEaNye0o0OB2hMbSCrIZgq2TUhbUy6ve4LQGBMmWU4ppMSmM2hWpN8wr-7x3OrO3ObXe9cwDSRQOQRJU5nQsEKw7Qp-udllXjU1'}});//]]>